A Mechanistic Approach to Preventing Schizophrenia in At-Risk Individuals  by Moghaddam, Bita
Neuron
PreviewsA Mechanistic Approach to Preventing
Schizophrenia in At-Risk IndividualsBita Moghaddam1,*
1Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA
*Correspondence: bita@pitt.edu
http://dx.doi.org/10.1016/j.neuron.2013.03.024
In this issue of Neuron, Schobel et al. (2013) report that excess hippocampal glutamate may cause transition
to psychosis in individuals at high risk for schizophrenia. Their data has implications for prevention strategies
and why stress often precipitates this transition.Recent advances in genetics, brain imag-
ing, and molecular analyses of postmor-
tem tissue have helped generate a
considerable body of information related
to the etiology and pathophysiology of
schizophrenia. But ‘‘information is not
knowledge,’’ and with this accumulating
information we have come to appreciate
the enormous complexity of genetic and
nongenetic causes of schizophrenia.
This has, invariably, led to reduced opti-
mism that we will discover treatments
that cure schizophrenia or even provide
better efficacy than current antipsychotic
medications. We also are beginning to
appreciate that, similar to other brain dis-
orders such as Parkinson’s or Alzheimer’s
disease, by the time schizophrenia pre-
sents itself at a behavioral level, the
neuronal damage may be irreversible.
Given this, one of our best chances for
improving the outcome of this illness is
to prevent its progression. In the last
decade, based on the work of McGorry
and Yung at University of Melbourne and
McGlashan and Miller at Yale, the clinical
field of schizophrenia has advanced to-
ward identifying individuals at the so-
called prodromal phase of the illness,
who are at high risk for psychosis (Cannon
et al., 2008). A critical implication of this
effort is that, by identifying and following
the clinical outcome of these individuals,
we may be able to identify risk factors
for psychosis (Addington and Heinssen,
2012; Kaur and Cadenhead, 2010). This
can be done both by using multimodal
noninvasive methods in at-risk individuals
to characterize changes in brain events
that occur before or during transition to
psychosis, as well as applying relevant
animal models to reveal potential bio-
logical mechanisms underlying thesechanges. It is hoped that this mechanistic
knowledge will, in turn, allow us to
develop safe and effective interventions
to prevent the emergence of psychosis
in these individuals.
The paper published in this issue of
Neuron (Schobel et al., 2013) represents
the new wave of translational studies
focused on the strategy of detection and
intervention for schizophrenia. The longi-
tudinal design of this study identified a
spatiotemporally concordant pattern of
hippocampal hypermetabolism and atro-
phy during the emergence of psychosis
in at-risk individuals. Using an animal
model that produced a similar pattern of
hippocampal disruption, the authors iden-
tified a potential mechanism—enhanced
glutamate availability—that may drive the
psychosis-associated progression from
hypermetabolism to atrophy. Given these
data, interventions that attenuate gluta-
mate availability may mitigate psychosis
in individuals at-risk for schizophrenia.
The clinical results by Schobel et al.
(2013) may also provide mechanistic
insight on recent work that links elevated
striatal dopamine availability to prodromal
signs of schizophrenia and to probability
of transition to psychosis (Egerton et al.,
2013). There have been reports of an
aberrant relationship between hippocam-
pal glutamate levels and striatal dopa-
mine availability in individuals at high risk
to develop schizophrenia (Stone et al.,
2010). Thus, the findings by Schobel
et al. (2013) suggest that enhanced hippo-
campal glutamate, in addition to causing
relatively localized atrophy, may also
drive the dopamine abnormalities that
accompany the transition to psychosis.
Animal models (Moghaddam et al.,
1997) and human postmortem studiesNeur(Longson et al., 1996) have long impli-
cated excess glutamate in cortical and
hippocampal regions in the pathophysi-
ology of schizophrenia. Although the
idea of hyperfunctionality of glutamate
synapses is counterintuitive to some
traditional views on glutamate neuro-
transmission and schizophrenia, the
mechanism has gained acceptance
because it is consistent with a number of
clinical findings. At a theoretical level,
this hyperfunctionality may serve as a
common pathway for the diverse genetic
causes of the illness (Moghaddam, 2003)
and is consistent with neurotoxic pro-
cesses including apoptosis that may
mediate cortical and hippocampal atro-
phy (Glantz et al., 2006). At a mechanistic
level, excess glutamate availability may
help explain other pathophysiological
findings in schizophrenia such as an
adaptive change in GABA interneuron
function reported in postmortem tissue
(Schobel et al., 2013), and imaging find-
ings of enhanced dopamine neurotrans-
mission (Howes et al., 2012), given that
dopamine neurons receive glutamate pro-
jections from hippocampus and prefrontal
cortex. Based, in part, on these previous
findings, reducing glutamate neuro-
transmission in schizophrenia through a
modulatory mechanism such as agonism
of metabotropic glutamate receptor 2
(mGlu2) has been in the conceptual pipe-
line for more than a decade. While the
approach of reducing glutamate availabil-
ity may not provide long-term efficacy
for treating psychosis in chronically ill
patients (Kinon and Go´mez, 2013), the
study by Schobel et al. (2013) suggests
it may be a useful approach as a preven-
tion strategy in individuals at high risk for
schizophrenia.on 78, April 10, 2013 ª2013 Elsevier Inc. 1
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Figure 1. The Risk Architecture of Schizophrenia Is Complex and Multifactorial
(A) A hypothetical map of genetic aberration in different populations of patients (P) where distinct common genetic (G) variants with small effects (shown in light
blue) and rare variants with large effects (dark blue) have been implicated in risk vulnerability.
(B) The epigenetic and environmental factors are equally complex. Some of the environmental influences that have been implicated at various stages of the illness
include nutrition (n), urbanicity (u), immune and inflammation responses (i), drug use (d), and stress (s). The contribution of these factors is most likely interactive or
synergistic.
(C) There are several ‘‘common pathway’’ hypotheses of schizophrenia where different genetic and environmental insults converge by disrupting a common
mechanism. One such hypothesis is the functional clustering of expression of proteins and other factors that influence glutamate availability in the synapse.
As demonstrated in the figure, this can involve a diverse group of proteins in different patients that form functional clusters (green) of glutamate-influencing pro-
teins. These clusters can influence a wide range of metabolic or degradation pathways for glutamine and glutamate, or the function of the glutamate synapse
through receptor, transporters, or signal transduction mechanisms.
(D) A consequence of this clustering is enhanced glutamate availability in affected regions, resulting in hypermetabolism as described by Schobel et al. (2013).
This hyperglutamatetgic (and hypermetabolic) state might only cause transient effects in at-risk individuals that are expressed as increased anxiety or cortical
noise that may produce cognitive deficits. Insults such as stress, which cause further glutamate release in vulnerable regions such as the hippocampus, may
push these levels beyond a threshold that can be cleared from the extracellular milieu. This excess glutamate may lead to spreading hypermetabolism and irre-
versible atrophy.
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be a pathogenic driver in at-risk individ-
uals may also provide a mechanism for
why first psychotic episodes in schizo-
phrenia often are manifested in response
to stress (Kaur and Cadenhead, 2010).
Extracellular levels of glutamate in hippo-
campus and prefrontal cortex are exqui-
sitely sensitive to stress. Under normal
conditions, the stress-induced increase
in glutamate efflux is cleared from the
extracellular spacewithinminutes (Bagley
and Moghaddam, 1997). However, if
genetic predisposition to schizophrenia
imparts an elevated tone of glutamate
neurotransmission by increasing extra-
cellular glutamate availability (Figure 1),
exposure to stress and the resulting in-
crease in glutamate can push the system
beyond a certain threshold that then leads
to atrophy. The glutamatergic link with
stress also suggests that nonpharmaco-
logic approaches should be taken seri-
ously as intervention strategies. Although
cognitive remediation trials are ongoing
in early stages of the illness (Addington
and Heinssen, 2012), a more comprehen-2 Neuron 78, April 10, 2013 ª2013 Elsevier Insive approach aimed at reducing stress
reactivity and anxiety may be more effec-
tive at this stage.
Excess glutamate may also lead to
oxidative stress and neuroinflammation
during the prodromal stage (Kaur and
Cadenhead, 2010). It is interesting that
treatments that target inflammation and
related mechanisms, such as dietary
omega-3 fatty acids, appear to be effec-
tive in reducing transition to psychosis
in at-risk individuals (Amminger et al.,
2010) despite having inconsistent or no
therapeutic efficacy in chronic patients.
On the other hand, treatments with com-
mon antipsychotic drugs do not seem to
be effective for preventing transition to
psychosis in at-risk individuals (Kaur and
Cadenhead, 2010). Insofar as ketamine-
induced glutamate release models some
aspects of the prodromal hippocampal
hypermetabolism (Schobel et al., 2013),
this lack of efficacy is not unexpected.
In similar animal models, antipsychotic
drugs, including clozapine, are not effec-
tive in reversing enhanced glutamate
release (Adams and Moghaddam, 2001).c.These drugs, in fact, can increase resting
extracellular levels of glutamate (Daly and
Moghaddam, 1993). Clearly, their use in
chronically ill patients may not adversely
affect glutamate release, but given that
the work by Schobel et al. (2013) makes
a strong case for excess glutamate to be
a pathogenic driver, use of antipsychotic
drugs may hasten the transition to psy-
chosis and, therefore, should be avoided
during the prodromal stage of the illness.
Prevention strategies are now com-
monplace in most fields of medicine.
This includes neurology, where dietary
and other lifestyle recommendations
have become mainstream for prevention
or reduction of illness progression for
brain disorders such as Alzheimer’s dis-
ease. Early identification of individuals
who are at high risk to develop schizo-
phrenia holds the promise of advancing
preventive treatment to psychiatry, and
in particular to prevention of schizo-
phrenia. Research so far indicates that
pathophysiological changes in the pro-
drome and first-episode patients may be
distinct from that observed in chronic
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Previewspatients (Kaur and Cadenhead, 2010) and
that early intervention with traditional
antipsychotic drugs may not only be inef-
fective, but may actually worsen the
outcome. This makes longitudinal and
mechanistically oriented translational
approaches such as that applied by
Schobel et al. (2013) especially critical
for the design of prevention strategies to
prevent psychosis in individuals at high
clinical risk for schizophrenia.
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It has been known for decades that a fraction of neuronal tubulin is insoluble in cold and also resistant to
calcium as well as drugs that depolymerize microtubules. In this issue of Neuron, Song et al. (2013) suggest
that this unusual stability results from the polyamination of tubulin by transglutaminase.For years, it was routine that each new
generation of microtubule researchers
would learn to make tubulin preps from
bovine or porcine brain (Miller andWilson,
2010). This would involve regular trips to a
slaughterhouse, waiting for the brains to
become available so that they could
immediately be put on ice and rushed
back to the lab, minced, and then put
into a blender with cold buffer. From
there, the strategy was based on the
simple principle that microtubules would
disassemble into soluble tubulin in the
cold and reassemble into microtubules
when the prep was warmed. Through
cycles of warming and cooling, the prep
would become progressively more en-riched for tubulin. For most microtubule
labs, those days are gone, because
molecular approaches can now accom-
plish what used to require this tedious
procedure. Reminiscing about those
earlier days brings to mind a fundamental
issue about tubulin andmicrotubules. The
initial huge pellet produced by spinning
down the brain homogenate was normally
washed down the drain without further
consideration—but this pellet actually
contained a significant amount of tubulin
that was not soluble in the cold. Although
this was long known, the cold-stable
tubulin fraction was given little attention
by most investigators—one notable ex-
ception being Scott Brady.Nearly three decades ago, Brady et al.
(1984) compared the biochemical proper-
ties of tubulin in the cold-stable fraction
with the properties of the temperature-
cycled tubulin. Much of the tubulin in the
cold-stable fraction was shown to be
extremely basic in charge, as assessed
by two-dimensional electrophoresis. Not
only was this different from the cycling
tubulin, but, for the ensuing decades, no
tubulin isoform produced by any tubulin
gene or posttranslational modification
became apparent that could explain this
behavior.
From biochemical studies alone, it
was impossible to know if the cold-insol-
uble tubulin represented a physiologicalon 78, April 10, 2013 ª2013 Elsevier Inc. 3
